SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 31st, 2018 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 9th, 2016 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June _____, 2016, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the “Company”), and [ ], a [ ] company, with its address [ ] (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2014 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Securities Purchase Agreement (this “Agreement”) is dated as of February 13, 2014, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and GEMINI MASTER FUND, LTD. a Cayman Islands Company (including its successors and assigns, “Purchaser”).
ContractInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations • California
THIS 10% CONVERTIBLE DEBENTURE is a duly authorized and validly issued 10% Convertible Debenture of Innovus Pharmaceuticals, Inc., a Nevada corporation, (the “Company”), having its principal place of business at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 designated as its 10% Convertible Debenture due 2015 (the “Debenture”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 13th, 2017 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [____ ____, 2017, between Innovus Pharmaceuticals, Inc. a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT INNOVUS PHARMACEUTICALS, INC.Common Stock Purchase • March 13th, 2017 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Engagement Agreement, dated January 17, 2017, as amended, between the Company and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC.
STRICTLY CONFIDENTIAL Innovus Pharmaceuticals, Inc.Letter Agreement • December 31st, 2018 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SERIES [A/B] COMMON STOCK PURCHASE WARRANT INNOVUS PHARMACEUTICALS, INC.Innovus Pharmaceuticals, Inc. • March 13th, 2017 • Pharmaceutical preparations
THIS SERIES [A/B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the [_____ year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ContractInnovus Pharmaceuticals, Inc. • March 16th, 2015 • Pharmaceutical preparations • Nevada
THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SUCH ACT AND ANY APPLICABLE STATE SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO INNOVUS PHARMACEUTICALS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 23rd, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of January 21, 2015, is entered into by and between Innovus Pharmaceuticals, Inc., a Nevada corporation, (the “Company”), and LYNNETTE DILLEN (the “Buyer”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 7th, 2019 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
June 24, 2016Letter Agreement • August 9th, 2016 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
SERIES [A/B/C PREFUNDED] COMMON STOCK PURCHASE WARRANTInnovus Pharmaceuticals, Inc. • December 31st, 2018 • Pharmaceutical preparations
THIS SERIES [A/B/C PREFUNDED] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) [and on or prior to 5:00 p.m. (New York City time) on eighteen (18) month anniversary of the Reverse Stock Split Date]1 [and on or prior to 5:00 p.m. (New York City time) on five and a half (5.5) year anniversary of the Reverse Stock Split Date]2 [and until this Warrant is exercised in full]3 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Sec
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 9th, 2016 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations
This Agreement is being entered into pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Buyer (the “Purchase Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • April 23rd, 2018 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is entered into by and between Ryan J. Selhorn (“you” or “your”) and Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”). This Agreement has an effective date of April 27, 2018 (the “Effective Date”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 15th, 2016 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 6, 2016, is entered into by and between Innovus Pharmaceuticals, Inc., a Nevada corporation, (the “Company”), and Vista Capital Investments, LLC (the “Buyer”).
Garden State Securities Inc. Red Bank, NJ 07707Innovus Pharmaceuticals, Inc. • August 9th, 2016 • Pharmaceutical preparations • Delaware
This letter sets forth the Agreement (the “Letter Agreement”) by and among Innovus Pharmaceuticals, Inc. and its subsidiaries and affiliates (collectively herein referred as the “Company”) and Garden State Securities Inc. and its subsidiaries and its affiliates (“GSS”) with respect to the engagement of GSS to act as a non-exclusive selling/placement agent for the Company.
Right to Purchase up to 250,000 Shares of Common Stock of Innovus Pharmaceuticals, Inc. (subject to adjustment as provided herein) COMMON STOCK PURCHASE WARRANTInnovus Pharmaceuticals, Inc. • March 28th, 2014 • Pharmaceutical preparations • California
This Warrant has been issued pursuant to the terms of that certain Securities Purchase Agreement, dated as of February 13, 2014 (the “Purchase Agreement”), by and among the Company and Purchaser party thereto, including the Holder. Capitalized terms not defined herein shall have the meanings given to them in the Purchase Agreement. As used herein the following terms, unless the context otherwise requires, have the following respective meanings:
AGREEMENT AND PLAN OF MERGER by and among AYTU BIOSCIENCE INC., AYTU ACQUISITION SUB, INC. and INNOVUS PHARMACEUTICALS, INC. Dated as of September 12, 2019Agreement and Plan of Merger • September 18th, 2019 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this "Agreement"), is entered into as of September 12, 2019, by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (the "Target"), Aytu Bioscience Inc., a Delaware corporation ("Aytu"), and Aytu Acquisition Sub, Inc., a Delaware corporation and a wholly-owned Subsidiary of Aytu ("Merger Sub"). Capitalized terms used herein (including in the immediately preceding sentence) and not otherwise defined herein shall have the meanings set forth in Section 8.01 hereof.
SHARE ISSUANCE AGREEMENTShare Issuance Agreement • September 2nd, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SHARE ISSUANCE AGREEMENT (the “Agreement”), is entered into as this 27th day of July, 2015, by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation, with headquarters located at 9171 Towne Centre Drive, Suite 440, San Diego, CA 92122 (the “Company”), and _____________a limited liability company, with its address ________________________ (the “Buyer”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • April 24th, 2013 • Innovus Pharmaceuticals, Inc. • Blank checks • California
This Asset Purchase Agreement (the “Agreement”), dated as of April 19, 2013, is by and between Centric Research Institute, Inc. a California corporation (“Seller”), and Innovus Pharmaceuticals, Inc. a Nevada corporation (“Purchaser”).
INNOVUS PHARMACEUTICALS, INC. MAY 2013 AMENDMENT TO 8% CONVERTIBLE DEBENTUREInnovus Pharmaceuticals, Inc. • August 13th, 2013 • Blank checks
THIS AMENDMENT TO 8% CONVERTIBLE DEBENTURE (“Amendment”) is entered into as of May 4, 2013 (the “Effective Date”), by and among Innovus Pharmaceuticals, Inc., a Nevada corporation ("Issuer"), and [ ] ("Debenture Holder").
AGREEMENT AND PLAN OF MERGER BY AND AMONG INNOVUS PHARMACEUTICALS, INC., INNOVUS PHARMA ACQUISITION CORPORATION, INNOVUS PHARMA ACQUISITION CORPORATION II, NOVALERE FP, INC., AND NOVALERE HOLDINGS, LLC DATED AS OF FEBRUARY 4, 2015Agreement and Plan of Merger • February 5th, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of February 4, 2015 (the “Agreement Date”), by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (“Acquiror”), Innovus Pharma Acquisition Corporation, a Delaware corporation (“Merger Sub One”) and a wholly owned subsidiary of Acquiror, Innovus Pharma Acquisition Corporation II, a Delaware corporation (“Merger Sub Two”) and a wholly owned subsidiary of Acquiror, Novalere FP, Inc., a Delaware corporation (“Target”), and Novalere Holdings, LLC, a Delaware limited liability company, as a representative of the stockholders of Target (“Holdings” or the “Stockholder Representative”).
VOTING AGREEMENTVoting Agreement • February 5th, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS VOTING AGREEMENT (this “Agreement”), is made as of the 4th day of February, 2015, by and among Innovus Pharmaceuticals, Inc., Nevada corporation (the “Company”), Novalere Holdings, LLC, a Delaware limited liability company (the “Stockholder”), and any transferees who become parties to this Agreement as “Stockholders” in accordance with Subsection 5(a) hereof.
INNOVUS PHARMACEUTICALS, INC. MAY 2013 AMENDMENT TO AMENDED AND RESTATED 8% CONVERTIBLE DEBENTUREInnovus Pharmaceuticals, Inc. • August 13th, 2013 • Blank checks
THIS MAY 2013 AMENDMENT TO AMENDED AND RESTATED 8% CONVERTIBLE DEBENTURE (“Amendment”) is entered into as of May 6, 2013 (the “Effective Date”), by and among Innovus Pharmaceuticals, Inc., a Nevada corporation ("Issuer"), and Bassam Damaj ("Debenture Holder").
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 31st, 2018 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 30, 2018, between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
REGISTRATION RIGHTS AND STOCK RESTRICTION AGREEMENTRegistration Rights and Stock Restriction Agreement • February 5th, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AND STOCK RESTRICTION AGREEMENT (this “Agreement”), is made as of the 4th day of February, 2015, by and among Innovus Pharmaceuticals, Inc., Nevada corporation ( “Acquiror”), Novalere Holdings, LLC, a Delaware limited liability company (“Stockholder”), and any transferees who become parties hereto as “Holders” in accordance with Subsection 4.1 below.
ContractInnovus Pharmaceuticals, Inc. • October 3rd, 2014 • Pharmaceutical preparations • New York
NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR THE SECURITIES LAWS OF ANY STATE AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE ARE CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER APPLICABLE FEDERAL AND STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE HOLDER TO SUCH EFFECT, WHICH OPINION SHALL BE REASONABLY ACCEPTABLE TO THE MAKER.
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • January 23rd, 2015 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment (this “Amendment”), is entered into as of January 21, 2015 and amends the Employment Agreement, dated as of January 22, 2013 (the “Employment Agreement”) by and between Innovus Pharmaceuticals, Inc., a Nevada corporation (the “Company”) and Bassam Damaj, a California citizen (“Dr. Damaj”).
MERGER AGREEMENT AND PLAN OF MERGERMerger Agreement and Plan of Merger • July 20th, 2011 • North Horizon, Inc. • Blank checks • Utah
THIS MERGER AGREEMENT AND PLAN OF MERGER (the “Agreement”) is made and entered into this 13th day of July 2011, by and between FasTrack, Inc., a corporation organized under the laws of the State of Delaware (hereafter “Fast”) and North Horizon, Inc., (hereinafter "North"), a corporation organized under the laws of the State of Nevada, and North First General, Inc, a wholly owned subsidiary of North (hereafter "Sub").
INNOVUS PHARMACEUTICALS, INC. EQUITY UNIT AGREEMENTEquity Unit Agreement • August 13th, 2013 • Innovus Pharmaceuticals, Inc. • Blank checks • California
THIS EQUITY UNIT AGREEMENT (this “Agreement”) is made and entered into as of May 15, 2013 (the “Effective Date”), by and between INNOVUS PHARMACEUTICALS, INC., a Nevada corporation (“Issuer”), and _____________, an individual (“Investor”).
STRICTLY CONFIDENTIAL Innovus Pharmaceuticals, Inc.Engagement Agreement • March 13th, 2017 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations
INNOVUS PHARMACEUTICALS, INC. AMENDMENT TO 8% CONVERTIBLE DEBENTUREInnovus Pharmaceuticals, Inc. • March 19th, 2013 • Blank checks
THIS AMENDMENT TO 8% CONVERTIBLE DEBENTURE (“Amendment”) is entered into as of January 12, 2013 (the “Effective Date”), by and among Innovus Pharmaceuticals, Inc., a Nevada corporation ("Issuer"), and [ ] ("Debenture Holder").
AGREEMENT AND PLAN OF MERGER BY AND AMONG INNOVUS PHARMACEUTICALS, INC., INNOVUS ACQUISITION CORPORATION, SEMPRAE LABORATORIES, INC., THE MAJOR STOCKHOLDERS AS DESCRIBED HEREIN ANDAgreement and Plan of Merger • December 30th, 2013 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • California
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of December 24, 2013 (the “Agreement Date”) by and among Innovus Pharmaceuticals, Inc., a Nevada corporation (“Acquiror”), Innovus Acquisition Corporation, a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Acquiror, Semprae Laboratories, Inc., a Delaware corporation (“Target”), the Major Stockholders of Target described on the signature pages to this Agreement (the “Major Stockholders”), and Quaker Bioventures II, L.P., a principal stockholder of Target (or its successor) (“Stockholders’ Agent”).
AMENDMENT TO THE $110,000 PROMISSORY NOTE DATED January 21, 2015Innovus Pharmaceuticals, Inc. • August 3rd, 2015 • Pharmaceutical preparations
The parties agree that the $110,000 Promissory Note by and between Innovus Pharmaceuticals, Inc. (“Company”) and Vista Capital Investments, LLC (“Holder”) is hereby amended as follows:
